EXPO enters August with its best monthly stretch in years — up nearly 9% on the week and almost 14% over the past month to close at $66.85 — yet the stock is still playing catch-up to a consulting sector that moved violently in both directions this week.
The most striking tension is not the rally itself, but what surrounds it. Peer HURN surged 35% on the week and CBZ added 29%, driven by deal-specific catalysts rather than any broad sector re-rating. EXPO's 8.8% weekly gain is respectable but structurally different — there is no single catalyst anchoring it. That gap between price action and narrative is where the interesting questions live.
Short interest and borrow conditions do nothing to complicate that story. EXPO's short interest has crept up about 41% over the past month to roughly 6% of the float — worth watching, but far from extreme. Borrow is cheap at 0.37% annually, down sharply from a month ago, and availability is extraordinarily loose at over 3,600%. That figure dwarfs even the 52-week floor of around 1,200%, meaning there is a vast pool of shares available to borrow relative to what is actually shorted. Options positioning tells a similar story of calm: the put/call ratio at 5.57 is slightly below its 20-day average of 6.04, sitting roughly half a standard deviation under the recent mean. Taken together, the lending market and options desk are relaxed — this rally has not attracted aggressive defensive hedging or a meaningful short rebuild.
The Street is split on direction after Thursday's quarterly results, and the divergence is blunt. JP Morgan raised its target from $80 to $90, maintaining Overweight — a direct response to the earnings beat that sent the stock up 1.5% the day results dropped. UBS moved the opposite way, cutting its target from $75 to $72 while holding Neutral, effectively saying the post-earnings pop has narrowed whatever buffer existed. The mean consensus target sits at $84, well above the current price, implying roughly 26% upside from here if the bull case plays out. Valuation multiples have expanded alongside the move: the trailing P/E now sits at 24.5x, up about 1.5 turns over the past month, while EV/EBITDA has actually compressed slightly to 16.6x as enterprise value adjusts. The dividend score ranks in the 87th percentile of the universe — though the dividend history in the data appears stale, with the most recent confirmed payment dating to 2022, so that ranking likely reflects the historical yield profile rather than current income. The short score of 44.6 has been virtually flat all week, consistent with an orderly, low-conviction short book rather than any squeeze dynamic.
Insider activity adds a modest cautionary note. The CEO, Catherine Corrigan, sold a combined 4,119 shares across June and July at prices between $57 and $63 — both well below the current $66.85. Those were small, low-significance transactions likely tied to planned selling, but they were executed into a declining stock and ahead of the earnings recovery. BlackRock holds 12.5% of shares and recently added about 62,000 shares, making it the most active large holder on record; the passive index flows are a steadier anchor than the executive selling is a warning.
The next earnings event is scheduled for late September. The setup heading into that print — a stock that just beat, analyst targets still dispersed, and a consulting sector that just demonstrated it can move 30%+ on individual catalysts — makes the quality of the Q3 revenue guidance the variable worth tracking most closely between now and then.
See the live data behind this article on ORTEX.
Open EXPO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
